Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gastrointestinal stromal tumour.

Brian P Rubin1, Michael C Heinrich, Christopher L Corless

  • 1Department of Anatomic Pathology, Taussig Cancer Center and the Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. rubinb2@ccf.org

Lancet (London, England)
|May 22, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

System for study of diverse cellular composition in alveolar rhabdomyosarcoma.

Scientific reports·2026
Same author

Dissecting the oncogenic function of YAP1 and WWTR1 fusion proteins in mammary epithelial cells.

Cancer letters·2026
Same author

Clinical and molecular features of primary gliosarcoma with digital spatial whole-transcriptome analysis of glial and mesenchymal components.

Brain pathology (Zurich, Switzerland)·2026
Same author

Genomic and Molecular Associations with Preoperative Immune Checkpoint Inhibition in Patients with Stage III Clear Cell Renal Cell Carcinoma.

Cancers·2026
Same author

A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway.

bioRxiv : the preprint server for biology·2025
Same author

CD117-Targeted Intraoperative Imaging of Gastrointestinal Stromal Tumor Using a Stem-Cell-Factor-Labeled Fluorophore.

Advanced nanobiomed research·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Gastrointestinal stromal tumors (GIST) are resistant to traditional treatments. Targeted therapies like imatinib show promise but face resistance, necessitating further research into molecular genetics and drug response.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Gastrointestinal stromal tumors (GIST) are the most common mesenchymal neoplasms of the GI tract.
  • GISTs exhibit high resistance to conventional chemotherapy and radiotherapy.
  • Activating mutations in KIT or PDGFRA receptor tyrosine kinases drive GIST development.

Purpose of the Study:

  • To review the molecular genetics of GIST.
  • To discuss the efficacy and limitations of targeted therapies like imatinib.
  • To highlight the role of GIST as a model for targeted therapy research.

Main Methods:

  • Review of literature on GIST molecular genetics.
  • Analysis of clinical data on imatinib and sunitinib efficacy.
  • Discussion of resistance mechanisms to targeted therapies.

Related Experiment Videos

Main Results:

  • KIT (75-80%) and PDGFRA (5-10%) mutations lead to constitutive kinase activation.
  • Imatinib mesylate is effective for recurrent/metastatic GIST and is being evaluated as adjuvant/neoadjuvant therapy.
  • Resistance to imatinib is a significant clinical challenge, with sunitinib as an alternative.

Conclusions:

  • Targeted therapies have transformed GIST treatment.
  • Understanding the interplay between GIST molecular genetics and drug response is crucial.
  • GIST serves as a valuable model for advancing targeted therapy strategies in other solid tumors.